Inflammatory Bowel Disease Treatment Market Outlook and Strategic Insights by 2031

The inflammatory bowel disease treatment market value is projected to grow from US$ 24.05 billion in 2023 to US$ 31.67 billion by 2031; the market is anticipated to record a CAGR of 3.50% from 2023 to 2031.

Market Insights and Analyst View:

Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract, including Crohn's disease and ulcerative colitis. These conditions cause inflammation of the digestive tract lining, leading to symptoms like abdominal pain, diarrhea, fatigue, and weight loss. Treatment aims to reduce inflammation, manage symptoms, and prevent complications through medication, lifestyle changes, and sometimes surgery. Managing IBD typically requires ongoing medical care and monitoring to maintain remission and improve quality of life. The key factors driving the Inflammatory Bowel Disease Treatment Market growth are the rising prevalence of Crohn's disease and ulcerative colitis, and the increasing number of product launches. This report includes growth prospects owing to the current Inflammatory Bowel Disease Treatment Market trends and their foreseeable impact during the forecast period. Technological advancements are likely to bring significant trends in the Inflammatory Bowel Disease Treatment Market in the coming years. Further, the development of innovative treatments through continuing research as well as encouraging government initiatives are also expected to fuel the market growth.

Growth Drivers and Challenges:

Crohn’s disease is a complex, chronic disorder that primarily affects the digestive system. The National Library of Medicine stated that there were 825 cases of IBD per 100,000 people in 2023, including compared to 410 cases of Crohn's disease and 414 cases of ulcerative colitis and IBD-u. With a prevalence of 0.82%, 322,600 Canadians were had IBD in 2023. Patients with gastrointestinal disease are at an increased risk of nutritional deterioration due to fasting requirements of diagnostic tests, therapeutic dietary restrictions, and loss of appetite due to anorexia or altered nutritional requirements caused due to the disease itself. Thus, enteral nutrition is prescribed for gastrointestinal disease patients, as the enteral route is preferred to provide the required nutrients. Therefore, the rising prevalence of Crohn’s disease and ulcerative colitis drives the growth of the Inflammatory Bowel Disease Treatment Market.

Crohn’s disease, gastrointestinal disease due to trauma, bowel obstruction (BO), microscopic colitis, short bowel syndrome, and ulcerative colitis are a few of the common gastrointestinal diseases. According to an article published in Healthline in 2021, ~40% of people across the world were affected by functional gastrointestinal disorders. The Canadian Digestive Health Foundation states millions of Canadians live with digestive diseases; ~20 million Canadians, i.e., 2 of every 3 people, suffer from digestive disorders yearly.

On the other hand, the high cost associated with treating inflammatory bowel disease (IBD) is a significant barrier in the IBD treatment market. From expensive medications to frequent hospitalizations and surgeries, managing IBD can place a heavy financial burden on patients and healthcare systems. The cost factor often limits access to optimal care and innovative treatments for many individuals living with IBD. Addressing the affordability and accessibility issues is crucial for improving outcomes and quality of life for patients affected by this chronic condition. Thus, the high cost associated with treatment hinders the Inflammatory Bowel Disease Treatment Market growth.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Inflammatory Bowel Disease Treatment Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Report Segmentation and Scope:

The Inflammatory Bowel Disease Treatment Market analysis has been carried out by considering the following segments: drug class, disease indication, and distribution channel. Based on geography, the Inflammatory Bowel Disease Treatment Market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Segmental Analysis:

Drug Class-Based Insights

Based on drug class, the market is segmented into biologics, aminosalicyclates, corticosteroids, and others. The biologics segment held the largest Inflammatory Bowel Disease Treatment Market share in 2023, and it is anticipated to register the highest CAGR during 2023–2031.

Disease Indication-Based Insights

Based on disease indication, the Inflammatory Bowel Disease Treatment Market is bifurcated into Crohn's disease and ulcerative colitis. The Crohn's disease segment is anticipated to hold a significant market share by 2031.

Disease Indication-Based Insights

Based on distribution channel, the market is classified hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is anticipated to hold a significant Inflammatory Bowel Disease Treatment Market share by 2031.

Inflammatory Bowel Disease Treatment Market Regional Insights

The regional trends and factors influencing the Inflammatory Bowel Disease Treatment Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Inflammatory Bowel Disease Treatment Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Inflammatory Bowel Disease Treatment Market Report Scope

Inflammatory Bowel Disease Treatment Market Players Density: Understanding Its Impact on Business Dynamics

The Inflammatory Bowel Disease Treatment Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Inflammatory Bowel Disease Treatment Market are:

1. Pfizer, Inc.,
2. Novartis AG,
3. AbbVie, Inc.,
4. Takeda Pharmaceuticals, Johnson and Johnson
5. , Celegene Corporation,
6. Bausch Health Companies

Disclaimer: The companies listed above are not ranked in any particular order.

Regional Analysis:

The geographic scope of the Inflammatory Bowel Disease Treatment Market report encompasses North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. In 2023, North America held the largest market share. Th US dominates the market in North America with the largest revenue share. The expanding Inflammatory Bowel Disease Treatment Market size in this country is attributed to an upsurge in the prevalence of inflammatory diseases, the presence of major market players and their strategic initiatives. Improved payment solutions, high treatment rates, rising prescription of innovative medications, uninterrupted research efforts, and favorable government initiatives also benefit the Inflammatory Bowel Disease Treatment Market in the US and other North American countries. Crohn's & Colitis Foundation is one of the noteworthy organizations dedicated to promoting clinical and translational research aimed at curing colitis and Crohn's disease.

Competitive Landscape and Key Companies:

The Inflammatory Bowel Disease Treatment Market forecast presented in this report can help stakeholders in this marketplace plan their growth strategies. AbbVie Inc, Takeda Pharmaceutical Company Limited, Pfizer Inc, Biogen, Novartis AG, Lilly, UCB S.A., CELLTRION INC., Merck & Co., Inc., and Johnson & Johnson Services, Inc. are a few key companies profiled in the Inflammatory Bowel Disease Treatment Market report. These companies focus on expanding their offerings to meet the growing consumer demand worldwide. Their global presence allows them to serve many customers, subsequently allowing them to expand their market presence.